← All State Street CORP filings

State Street CORP Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NYSE
STT
State Street CORP
SCHEDULE: State Street Reports Minor Stake in Astronix Corp
State Street Corporation and its affiliate SSGA Funds Management, Inc. have filed a Schedule 13G, disclosing a passive, non-controlling ownership of 0.1% in Astronix Corp.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 6.5% Stake in World Kinect Corp
State Street Corporation has reported a beneficial ownership of 6.5% in World Kinect Corp's common stock as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Corp. Reports Stake in Wolfspeed
State Street Corporation has updated its Schedule 13G filing to reflect its beneficial ownership of Wolfspeed Inc. common stock as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Reports Williams-Sonoma Stake
State Street Corporation has updated its beneficial ownership filing for Williams-Sonoma Inc., reporting a significant stake in the company's common stock.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses Stake in Westamerica Bancorp
State Street Corporation has updated its Schedule 13G filing to report beneficial ownership of 5.9% of Westamerica Bancorp's common stock.
NYSE
STT
State Street CORP
SCHEDULE: State Street Reports 5.8% Stake in Wesbanco
State Street Corporation has disclosed beneficial ownership of 5,616,212 shares, representing 5.8% of Wesbanco Inc.'s common stock, as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses Vistra Corp Stake
State Street Corporation has updated its beneficial ownership filing for Vistra Corp, reporting a significant stake in the company's common stock.
NYSE
STT
State Street CORP
SCHEDULE: State Street Reports 5.5% Stake in Viridian Therapeutics
State Street Corporation has disclosed beneficial ownership of 5.5% of Viridian Therapeutics Inc.'s common stock as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses Virgin Galactic Stake
State Street Corporation and SSGA Funds Management, Inc. have reported their beneficial ownership of Virgin Galactic Holdings Inc. common stock as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Corp Reports 5.9% Stake in Vir Biotechnology
State Street Corporation has disclosed beneficial ownership of 5.9% of Vir Biotechnology Inc.'s common stock as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Reports 5.8% Stake in Verastem Inc.
State Street Corporation has disclosed beneficial ownership of 5.8% of Verastem Inc.'s common stock, holding over 5.1 million shares.
NYSE
STT
State Street CORP
SCHEDULE: State Street Reports 5.8% Stake in Vera Therapeutics
State Street Corporation has disclosed beneficial ownership of 5.8% of Vera Therapeutics Inc. common stock as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses Stake in Ur-Energy
State Street Corporation and its affiliate SSGA Funds Management, Inc. have updated their beneficial ownership filings for Ur-Energy Inc., reporting a combined 6.6% stake.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 6.4% Stake in Uranium Energy Corp
State Street Corporation has reported beneficial ownership of 6.4% of Uranium Energy Corp's common stock as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Reports Stake in UnitedHealth Group
State Street Corporation has updated its beneficial ownership filing for UnitedHealth Group common stock, reporting a 5% stake as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses Stake in US Antimony Corp
State Street Corporation and SSGA Funds Management, Inc. have updated their Schedule 13G filing, reporting a combined beneficial ownership of 7.7% in United States Antimony Corp.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses 6.3% Stake in Ultragenyx
State Street Corporation has reported beneficial ownership of 6,158,766 shares, representing 6.3% of the outstanding common stock of Ultragenyx Pharmaceutical Inc., as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses Trimble Stake
State Street Corporation has filed a Schedule 13G, reporting beneficial ownership of 11,656,926 shares of Trimble Inc. common stock, representing approximately 5% of the class.
NYSE
STT
State Street CORP
SCHEDULE: State Street Reports 4.6% Stake in Travere Therapeutics
State Street Corporation has disclosed beneficial ownership of 4.6% of Travere Therapeutics Inc.'s common stock as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Reports 6.2% Stake in TKO Group Holdings
State Street Corporation has disclosed beneficial ownership of 6.2% of TKO Group Holdings' common stock as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses Macerich Stake
State Street Corporation has filed a Schedule 13G, reporting beneficial ownership of 5.5% of Macerich Co. common stock as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Corp Reports 5.6% Stake in T1 Energy Inc.
State Street Corporation has disclosed beneficial ownership of 5.6% of T1 Energy Inc.'s common stock as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Corp. Discloses Stake in Syndax Pharmaceuticals
State Street Corporation has updated its beneficial ownership filing for Syndax Pharmaceuticals Inc., reporting a 6.4% stake as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Reports 5.4% Stake in Smurfit Westrock
State Street Corporation has disclosed beneficial ownership of 5.4% of Smurfit Westrock PLC's common stock as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Reports SM Energy Stake
State Street Corporation has updated its beneficial ownership filing for SM Energy Co., reporting a 4.9% stake as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Reports 7% Stake in Sellas Life Sciences
State Street Corporation has disclosed beneficial ownership of 7% of Sellas Life Sciences Group Inc.'s common stock as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Reports 5.5% Stake in Satellogic
State Street Corporation has reported beneficial ownership of 5.5% of Satellogic Inc.'s common stock as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Discloses Sarepta Therapeutics Stake
State Street Corporation and its affiliate SSGA Funds Management, Inc. have filed a Schedule 13G, reporting beneficial ownership of Sarepta Therapeutics Inc. common stock.
NYSE
STT
State Street CORP
SCHEDULE: State Street Reports 5.1% Stake in Sable Offshore Corp
State Street Corporation has disclosed beneficial ownership of 5.1% of Sable Offshore Corp's common stock as of June 30, 2026.
NYSE
STT
State Street CORP
SCHEDULE: State Street Reports 5.2% Stake in S&T Bancorp
State Street Corporation has disclosed beneficial ownership of 5.2% of S&T Bancorp's common stock as of June 30, 2026.